192 related articles for article (PubMed ID: 10967161)
1. Adverse drug events and near misses: who's counting?
Wu AW
Am J Med; 2000 Aug; 109(2):166-8. PubMed ID: 10967161
[No Abstract] [Full Text] [Related]
2. How many deaths occur annually from adverse drug reactions in the United States?
Chyka PA
Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153
[TBL] [Abstract][Full Text] [Related]
3. Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.
Meier L; Wang EY; Tomes M; Redberg RF
JAMA Intern Med; 2020 Jan; 180(1):147-148. PubMed ID: 31589249
[TBL] [Abstract][Full Text] [Related]
4. Drug makers' adverse event reports are often incomplete, US report finds.
McCarthy M
BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
[No Abstract] [Full Text] [Related]
5. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
[TBL] [Abstract][Full Text] [Related]
6. Drug-related deaths in a university central hospital.
Juntti-Patinen L; Neuvonen PJ
Eur J Clin Pharmacol; 2002 Oct; 58(7):479-82. PubMed ID: 12389071
[TBL] [Abstract][Full Text] [Related]
7. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
8. National adverse drug reaction reporting. 1984-1989.
Faich GA
Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
[TBL] [Abstract][Full Text] [Related]
9. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
Woo EJ; Moro PL; Cano M; Jankosky C
Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
[TBL] [Abstract][Full Text] [Related]
10. Monitoring drug product quality.
Bolger G; Goetsch R; Reinstein P
Am Pharm; 1992 Feb; NS32(2):47-9. PubMed ID: 1546630
[No Abstract] [Full Text] [Related]
11. Sequential surveillance for drug safety in a regulatory environment.
Martin D; Gagne JJ; Gruber S; Izem R; Nelson JC; Nguyen MD; Ouellet-Hellstrom R; Schneeweiss S; Toh S; Walker AM
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):707-712. PubMed ID: 29504168
[No Abstract] [Full Text] [Related]
12. Therapeutic ineffectiveness: heads or tails?
Figueras A; Pedrós C; Valsecia M; Laporte JR
Drug Saf; 2002; 25(7):485-7. PubMed ID: 12093306
[TBL] [Abstract][Full Text] [Related]
13. Reporting of adverse events to MedWatch.
Piazza-Hepp TD; Kennedy DL
Am J Health Syst Pharm; 1995 Jul; 52(13):1436-9. PubMed ID: 7671043
[TBL] [Abstract][Full Text] [Related]
14. Role of postmarketing surveillance in contemporary medicine.
Woodcock J; Behrman RE; Dal Pan GJ
Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
[TBL] [Abstract][Full Text] [Related]
15. Suspected adverse reactions, 2007.
Dyer F; Spagnuolo-Weaver M; Coolees S; Tait A
Vet Rec; 2008 Jul; 163(3):69-72. PubMed ID: 18702197
[No Abstract] [Full Text] [Related]
16. Poisons centres and the reporting of adverse drug events: the case for further development.
Volans GN; Karalliedde L; Wiseman HM
Drug Saf; 2007; 30(3):191-4. PubMed ID: 17343427
[No Abstract] [Full Text] [Related]
17. FDA gets advice on Modernization Act compliance.
Marwick C
JAMA; 1998 Oct; 280(14):1214-5. PubMed ID: 9786361
[No Abstract] [Full Text] [Related]
18. Reported adverse drug events in infants and children under 2 years of age.
Moore TJ; Weiss SR; Kaplan S; Blaisdell CJ
Pediatrics; 2002 Nov; 110(5):e53. PubMed ID: 12415059
[TBL] [Abstract][Full Text] [Related]
19. Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).
Egeberg A; Thyssen JP
Br J Dermatol; 2023 May; 188(6):793-794. PubMed ID: 36797979
[No Abstract] [Full Text] [Related]
20. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
[Next] [New Search]
